P. Hurteloup

发表

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Julio Astudillo, Jean-Yves Douillard, Vito Lorusso, 2006, The Lancet. Oncology.

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

P. Vrignaud, L. Mauriac, J. Robert, 1985, Cancer treatment reports.

Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients.

J. Reiffers, P. Hurteloup, P. Collombat, 1991, Leukemia and Lymphoma.

Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer

M. Namer, M. Marty, A. Monnier, 1990, American journal of clinical oncology.

Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.

J. Reiffers, P. Hurteloup, N. Ifrah, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.

J. Reiffers, J. Robert, P. Hurteloup, 1987, Leukemia research.

Preoperative chemotherapy in the treatment of inflammatory breast cancer.

P. Hurteloup, R. Keiling, N. Guiochet, 1985, Progress in clinical and biological research.

A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients

P. Hurteloup, J. Harousseau, Z. Tellier, 1998 .

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.

J. Reiffers, P. Berthaud, P. Hurteloup, 1996, Leukemia.

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

P. Hurteloup, J. Harousseau, Z. Tellier, 1998, Blood.

Prospective Comparison of Allogeneic Bone Marrow Transplantation, Intensive Consolidation Chemotherapy, and Unpurged Autologous Bone Marrow Transplantation as Post-Remission Therapy in Adult Acute Myeloid Leukemia

P. Berthaud, P. Hurteloup, N. Ifrah, 1997 .

Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Treatment for Elderly Patients with Acute Myeloid Leukemia

C. Gardin, P. Hurteloup, N. Ifrah, 1997 .

Oral Idarubicin and Low Dose Cytarabine as the Initial Treatment of Acute Myeloid Elderly Patients in Leukemia

J. Reiffers, P. Hurteloup, P. Collombat, 1991 .

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.

J. Reiffers, P. Hurteloup, P. Dufour, 1987, Cancer treatment reports.

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

P. Hurteloup, J. Abgrall, P. Hervé, 1997, Blood.

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

J. Armand, J. Robert, P. Hurteloup, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of acute myelogenous leukaemia in patients aged 50–65: idarubicin is more effective than zorubicin for remission induction and prolonged disease‐free survival can be obtained using a unique consolidation course

P. Berthaud, P. Hurteloup, P. Hervé, 1996, British journal of haematology.

Phase II clinical evaluation of doxifluridine.

S. Schraub, J. Armand, P. Fumoleau, 1986, Cancer treatment reports.

Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.

P. Hurteloup, F. Ganzina, 1986, Drugs under experimental and clinical research.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

S. Culine, J. Carles, J. Bellmunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate

P. Hurteloup, P. Chollet, H. Roché, 1993 .

Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia

P. Cony-Makhoul, J. Reiffers, P. Hurteloup, 1992 .

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.

R. Rosell, J. Douillard, M. de Lena, 2008, International journal of radiation oncology, biology, physics.

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

P. Hurteloup, N. Milpied, J. Harousseau, 1989, European journal of haematology.

Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

M. Glabbeke, J. Armand, P. Hurteloup, 1989 .

Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.

J. Robert, P. Hurteloup, F. Rigal‐Huguet, 1990, Leukemia.

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience.

P. Hurteloup, J. Harousseau, Z. Tellier, 1996, Hematology and cell therapy.

Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma.

J. Bergerat, P. Berthaud, P. Hurteloup, 1996, Leukemia & lymphoma.

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

J. Robert, P. Hurteloup, F. Rigal‐Huguet, 1992, Hematological oncology.

Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.

T. Delozier, P. Fumoleau, P. Hurteloup, 1995, Seminars in oncology.

Postmenopausal Patients with Node-Positive Resectable Breast Cancer

M. Héry, M. Namer, A. Monnier, 2012, Drugs.

Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.

M. Namer, G. Milano, P. Hurteloup, 1991, Journal of pharmaceutical sciences.

AbstractPlenary 3: Impact of Radiation on Survival After Complete Resection of Non–Small-Cell Lung Cancer: Descriptive Analysis in the Randomized Adjuvant Chemotherapy Trial, ANITA 1

R. Rosell, J. Douillard, M. Riggi, 2006 .

Cost Utility in Second-Line Metastatic Breast Cancer

G. Berdeaux, P. Hurteloup, 1997, PharmacoEconomics.

Phase II clinical evaluation of 4'-epi-doxorubicin.

J. Armand, P. Hurteloup, G. Mathé, 1983, Cancer treatment reports.

INTENSIVE INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS

J. Reiffers, P. Hurteloup, A. Stoppa, 1992 .